Peroxisome Proliferator-Activated Receptor (PPAR) alpha/gamma Agonist.
- Author:
Jihyun LEE
1
Author Information
1. Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. jhlee9@cu.ac.kr
- Publication Type:Review
- Keywords:
PPAR alpha/gamma agonist;
Diabetic dyslipidemia;
Insulin resistance;
Aleglitazar
- MeSH:
Acute Coronary Syndrome;
Dyslipidemias;
Fractures, Bone;
Glucose;
Heart Failure;
Homeostasis;
Humans;
Hyperglycemia;
Inflammation;
Insulin Resistance;
Lipoproteins;
Outcome Assessment (Health Care);
Peroxisome Proliferator-Activated Receptors;
Peroxisomes*;
Risk Factors;
Weight Gain
- From:Korean Journal of Medicine
2014;87(1):19-25
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Peroxisome proliferator-activated receptor (PPAR) agonists improve glucose control and insulin sensitivity, reduce concentrations of atherogenic lipoproteins, and decrease circulating levels of inflammatory mediators. PPAR activation is considered an important pharmacologic target for patients with type 2 diabetes. However, the PPAR agonists in clinical use have undesirable side effects, including weight gain, heart failure, and bone fractures. PPAR alpha/gamma dual agonists each target one or more of the key cardiometabolic risk factors of diabetic dyslipidemia, insulin resistance, hyperglycemia, and inflammation; thus, combining their benefits to provide glucose control and ameliorate cardiovascular risks has emerged as an attractive treatment option. Aleglitazar, which was designed to balance the activation of PPAR alpha/gamma, proved efficacious in improving glycemic control and lipid homeostasis and is anticipated to minimize PPAR-related side effects. Whether the effects of aleglitazar on cardiometabolic risk factors translate into improved cardiovascular outcomes, particularly in high-risk patients, is currently being evaluated by AleCardio, a large, long-term, time-, and event-driven outcome study of type 2 diabetics with recent acute coronary syndrome.
